News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequent Medical Inc. and Collaborators Presented Key Data Using a Novel Sequencing Technology to Predict Clinical Relapse


12/13/2011 7:49:47 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc., announced at the annual meeting of the American Society of Hematology (ASH) the results from several studies showing the sensitivity and specificity of the company’s Immune Cell Receptor Sequencing (ICRS) platform in detecting Minimal Residual Disease (MRD) and predicting clinical relapse in childhood and adult Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) patient samples.

Read at BioSpace.com


comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES